Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3581043

COc1c(C(C)(C)C)cc(-c2nc(C3CCN(C(=O)Cn4cc(C)c(CC(=O)O)n4)CC3)cs2)cc1C(C)(C)C.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F

nearest known ligand 0.36

Full drug profile on Sugi Atlas →

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 11/20 0.36
CCR1 P32246 1/20 0.31
KHK P50053 2/20 0.30
LMNA P02545 1/20 0.30
SHMT1 P34896 1/20 0.30
GRIN1 Q05586 1/20 0.30
GRIN2B Q13224 1/20 0.30
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
GAA P10253 1/20 0.30
HPGD P15428 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3586453 0.90 IRAK4 (0.39) IRAK4
SCHEMBL13031179 0.82 IRAK4 (0.33) IRAK4GRIN2B
Hydrochloric Acid SCHEMBL3591188 0.81 CPT1A (0.34) LMNASHMT1KDM4EALDH1A1GAA
SCHEMBL3591790 0.79 PSEN1 (0.36) IRAK4LMNAGRIN1GRIN2BKDM4E
Hydrochloric Acid SCHEMBL3585764 0.78 CPT1A (0.33) IRAK4KDM4EALDH1A1GAAHPGD
SCHEMBL3581627 0.78 IRAK4 (0.33) IRAK4LMNAGRIN1GRIN2BKDM4E
SCHEMBL3576143 0.78 CXCR3 (0.36) IRAK4
SCHEMBL3588152 0.78 CXCR3 (0.38) IRAK4CCR1LMNAALDH1A1GAA
SCHEMBL3593480 0.78 CPT1A (0.35) KDM4EALDH1A1HPGD
SCHEMBL3595199 0.77 GRIN1 (0.34) IRAK4LMNAGRIN1GRIN2BKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642634-B2 Fungicidal azocyclic amides E I DU PONT DE NEMOURS AND COMPANY (US) 2014-02-04 US claimed
US-20100286191-A1 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators MERCK SHARP & DOHME CORP. 2010-11-11 US claimed
US-20100286191-A1 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators MERCK SHARP & DOHME CORP. 2010-11-11 US disclosed
EP-1962605-A2 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS Merck & Co., Inc. (US) 2008-09-03 EP disclosed
WO-2007070433-A2 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS MERCK & CO., INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286191-A1 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators CXCR3, CXCR1, CXCR2 IRAK4 367/4885CCR1 8/4885KHK 3964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.